Details

Autor(en) / Beteiligte

• Wyles, David L
• Ruane, Peter J
• Sulkowski, Mark S
• Dieterich, Douglas
• Luetkemeyer, Anne
• Morgan, Timothy R
• Sherman, Kenneth E
• Dretler, Robin
• Fishbein, Dawn
• Gathe, Joseph C
• Henn, Sarah
• Hinestrosa, Federico
• Huynh, Charles
• McDonald, Cheryl
• Mills, Anthony
• Overton, Edgar Turner
• Ramgopal, Moti
• Rashbaum, Bruce
• Ray, Graham
• Scarsella, Anthony
• Yozviak, Joseph
• McPhee, Fiona
• Liu, Zhaohui
• Hughes, Eric
• Yin, Philip D
• Noviello, Stephanie
• Ackerman, Peter

Titel

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Ist Teil von

• The New England journal of medicine, 2015-08, Vol.373 (8), p.714-725

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Among patients coinfected with HIV-1 and HCV, a sustained HCV virologic response was reported in 97% of patients treated with 12 weeks of daclatasvir plus sofosbuvir. Liver disease is a leading cause of death among patients with human immunodeficiency virus type 1 (HIV-1) infection. 1 Coinfection with HIV-1 and hepatitis C virus (HCV) appears to accelerate the course of HCV-associated liver disease 2 – 5 and is widespread, particularly among injection-drug users. 6 The effect of HIV-1 coinfection on the course of HCV disease is reduced but not eliminated by antiretroviral therapy. 7 , 8 Adoption of interferon-based HCV treatments has been low among HIV–HCV coinfected patients 9 , 10 owing to a high adverse-event burden. 11 Furthermore, the rate of sustained virologic response to interferon–ribavirin is lower among patients with HIV–HCV coinfection than among . . .